- Total revenue of $19.3 million
versus $21.1 million in Q1
2022
- Adjusted EBITDA(1) of $1.3
million versus $2.9 million in
Q1 2022
- Net loss of $3.9 million
compared to a net loss of $0.6
million in Q1 2022
- Adjusted Net Income (Loss) (1) of ($2.4) million versus Adjusted Net Income of
$0.1 million in Q1 2022
VAUGHAN, ON,
May 11,
2023 /CNW/ - MAV Beauty Brands Inc. ("MAV Beauty
Brands" or the "Company"), a global personal care company, today
announced its financial results for the three months ended
March 31, 2023. Unless otherwise
indicated, all amounts are expressed in U.S. dollars. Certain
metrics, including those expressed on an adjusted basis, are
non-IFRS measures (see "Non-IFRS Measures" below).
"Our sales results for the first quarter reflect the continuing
impact of distribution losses and broader macroeconomic challenges,
notably higher interest rates," said Serge
Jureidini, President & CEO of MAV Beauty Brands. "While
we continue to have areas of strength across the portfolio,
including solid performance from our largest brand, our team is
focused on the execution of our strategies to strengthen each of
the brands, with an emphasis on product innovation and marketing.
At the same time, we continue to advance our ongoing cost saving
initiatives, which we believe will positively impact gross margins
and operating profitability."
Selected Financial Highlights(1)(2)
(in thousands of US
dollars except per share amounts)
(unaudited)
|
Q1
2023
|
Q1
2022
|
|
|
|
Revenue
|
19,255
|
21,137
|
Gross
profit
|
7,839
|
9,317
|
Net (loss) for the
period
|
(3,869)
|
(632)
|
Loss per Share
(basic)
|
(0.10)
|
(0.02)
|
Adjusted
EBITDA
|
1,282
|
2,873
|
Cash flow (use) from
operating activities
|
(63)
|
3,728
|
Free Cash Flow and
Adjusted Free Cash Flow
|
(108)
|
3,681
|
Adjusted Net Income
(Loss)
|
(2,386)
|
86
|
|
|
|
(1)
|
EBITDA (used below),
Adjusted EBITDA, Free Cash Flow, Adjusted Free Cash Flow, Adjusted
Net Income (Loss), Adjusted Net Income (Loss) per Share (diluted),
and Net Debt (used below) are each non-IFRS measures and are not
earning measures recognized by IFRS. Further information about
non-IFRS measures and definitions of the non-IFRS measures used in
this press release can be found under the heading "Non-IFRS
Measures" in this press release. Reconciliations of non-IFRS
measures to the relevant reported measures prepared in accordance
with IFRS can be found in this press release under the headings "Q1
2023 Compared to Q1 2022". See also the heading "How We Assess the
Performance of Our Business" on page 7, and the heading "Non-IFRS
Measures" on page 9 of our Management's Discussion and Analysis for
the three-month period ended March 31, 2023.
|
(2)
|
Earnings per share
(basic) calculation does not include the impact of 2,463,963 common
shares of the Company issuable upon the exchange of the units
issued as part of The Mane Choice
acquisition.
|
Q1 2023 Business and Financial Review
Q1 2023 total revenue was $19.3
million, compared to $21.1
million in Q1 2022. For the Canada/US region, revenue decreased by 9.3% to
$18.0 million in Q1 2023, compared to
$19.9 million in Q1 2022. For the
International region, revenue was $1.2
million, compared to $1.3
million in Q1 2022. Revenue decreases year over year
principally reflect the impact of loss of distribution in the US
mass and drug channels.
Gross profit was $7.8 million in
Q1 2023 (40.7% margin), compared to $9.3
million (44.1% margin) reported in Q1 2022. The lower gross
profit margin in Q1 2023 mainly reflects the impact of sales mix in
the quarter, as well as increased supply chain input costs. The
Company continues to closely monitor the impact of inflation on
supply chain input costs, and is implementing select price
increases and procurement cost savings initiatives.
Adjusted EBITDA(1) decreased to $1.3 million in Q1 2023, from $2.9 million in Q1 2022, mainly due to lower
revenue and gross margin.
In Q1 2023, the Company reported a net loss of $3.9 million, versus a net loss of $0.6 million in Q1 2022. As a result of the
changes in the interest rate and payment terms in the Q1 2023
amendment and extension of its credit facilities, the Company
recalculated the carrying amount of the total obligation and
recorded a loss on modification totaling $1.5 million in the quarter.
Adjusted Net Income (Loss) (1) for Q1 2023 was
($2.4) million, compared with
Adjusted Net Income of $0.1 million
in Q1 2022, due to the factors discussed above.
Cash from operating activities was a loss of $0.1 million in Q1 2023, a decrease from positive
$3.7 million in Q1 2022, reflecting
lower Adjusted EBITDA and higher cash interest. Adjusted Free Cash
Flow(1) decreased to a net use of $0.1 million in Q1 2023, compared to $3.7 million in Q1 2022.
At quarter end, Cash was $8.3
million and Net Debt(1) was $115.6 million, compared with $115.0 as at December 31,
2022. As previously disclosed with its fiscal 2022 financial
results, MAV initiated a strategic review process to identify,
review and evaluate potential strategic alternatives that may be
available to the Company and amended and extended its credit
facilities in March 2023. The amended
and extended credit facilities are available under the Company's
profile at www.sedar.com and are described in our Management's
Discussion and Analysis for the three months ended March 31, 2023. See "Forward-Looking
Information".
Financial Statements and Management's Discussion and
Analysis
The Company's unaudited condensed consolidated interim financial
statements for the three months ended March
31, 2023 are available under the Company's profile on SEDAR
at www.sedar.com and on MAV Beauty Brands' investor relations
website at investors.mavbeautybrands.com.
Conference Call & Webcast
MAV Beauty Brands will host a conference call to discuss its
fiscal 2023 first quarter financial results at 8:30 a.m. EDT on May 11,
2023. To participate in the call, dial 416-764-8650 or
888-664-6383 using the conference ID 58689724. The audio webcast
can be accessed at investors.mavbeautybrands.com.Listeners should
access the webcast or call 10-15 minutes before the start time to
ensure they are connected.
About MAV Beauty Brands (TSX:MAV)
MAV Beauty Brands is a global personal care platform focused on
managing great independent brands to scale and win market share
through product innovation, marketing and expanded distribution.
Today, MAV Beauty Brands markets a diversified portfolio of four
complementary personal care brands – Marc Anthony True
Professional, Renpure, Cake Beauty and The Mane Choice – offering
premium quality hair care, face and body care beauty products.
These products are sold in over 25 countries around the world and
in many major retailers.
Non–IFRS Measures
This press release makes reference to certain non–IFRS measures.
These measures are not recognized measures under IFRS, do not have
a standardized meaning prescribed by IFRS and are therefore
unlikely to be comparable to similar measures presented by other
companies. Rather, these measures are provided as additional
information to complement those IFRS measures by providing further
understanding of our results of operations from management's
perspective. Accordingly, these measures should not be considered
in isolation nor as a substitute for analysis of our financial
information reported under IFRS. We use non–IFRS measures including
"Adjusted Net Income (Loss) Per Share (Diluted)", "Adjusted
EBITDA", "Adjusted Free Cash Flow", "Adjusted Net Income (Loss)",
"EBITDA", "Free Cash Flow" and "Net Debt". These non–IFRS measures
are used to provide investors with supplemental measures of our
operating performance and thus highlight trends in our core
business that may not otherwise be apparent when relying solely on
IFRS financial measures. We also believe that securities analysts,
investors, and other interested parties frequently use non–IFRS
measures in the evaluation of issuers. Our management also uses
non–IFRS measures in order to facilitate operating performance
comparisons from period to period, to prepare annual operating
budgets and to determine components of management compensation.
Definitions and reconciliations of non-IFRS measures to the
relevant reported measures prepared in accordance with IFRS can be
found under the headings "Non-IFRS Measures" and "Q1 2023 Compared
to Q1 2022" in this press release. See also our Management's
Discussion and Analysis under the headings "How We Assess the
Performance of Our Business" on page 7, and "Non-IFRS Measures" on
page 9.
"Adjusted Net Income (Loss) Per Share (Diluted)" is
computed similarly to basic earnings per share except that the
weighted average number of shares outstanding is increased to
include additional shares for the assumed conversion of preference
shares, proportionate voting shares, and exchangeable shares and
exercise of stock options, if dilutive. The average number of
shares is calculated by assuming that outstanding conversions were
exercised and that the proceeds from such exercises were used to
acquire common shares at the average market price during the
reporting period. We believe Adjusted Net Income (Loss) Per Share
(Diluted) is a useful measure to assess the performance of our
Company as it provides meaningful operating results per diluted
share and facilitates period-to-period operating comparisons.
"Adjusted EBITDA" represents, for the applicable
period, EBITDA before certain expenses, costs, charges or benefits
incurred in such period which in management's view are not
indicative of continuing operations, including:
(i) integration, restructuring, and other costs;
(ii) purchase accounting adjustments; (iii) share–based
compensation; (iv) impairment of goodwill; and (v) unrealized
foreign exchange (loss) gain. We believe Adjusted EBITDA is a
useful measure to assess the performance of our Company as it
provides meaningful operating results and facilitates
period-to-period operating comparisons.
"Adjusted Free Cash Flow" is calculated as Free Cash Flow
adjusted to add back acquisition related costs which are included
in cash provided by operating activities. We believe Adjusted free
cash flow is a useful measure to assess the Company's ability to
repay debt, finance strategic business acquisitions and
investments, pay dividends and repurchase shares. It also
facilitates period-to-period comparisons.
"Adjusted Net Income (Loss)" represents, for the
applicable period, net income (loss) as adjusted to add back or
deduct, as applicable, certain expenses, costs, charges or benefits
incurred in such period which in management's view are not
indicative of continuing operations, including: (i) integration,
restructuring, and other costs; (ii) purchase accounting
adjustments; (iii) share–based compensation; (iv) impairment of
goodwill; (v) unrealized foreign exchange loss (gain); and
(vi) tax impacts of the aforementioned adjustments (based on
annual effective tax rate). We believe Adjusted Net Income
(Loss) is a useful measure to assess the performance of our Company
as it provides meaningful operating results and facilitates
period-to-period operating comparisons.
"EBITDA" represents net income (loss) for the period
before: (i) income tax expense (recovery); (ii) interest
and accretion; and (iii) amortization and depreciation.
''Free Cash Flow'' represents, for the applicable period,
cash provided by operating activities less cash used to purchase
property and equipment. Free cash flow is a key metric used by the
investing community that measures the Company's ability to repay
debt, finance strategic business acquisitions and investments, pay
dividends and repurchase shares.
"Net Debt" is calculated as long-term debt before
unamortized deferred financing costs less cash as reported in the
consolidated statements of financial position. We believe Net
Debt is a useful measure is an important measure as it reflects the
principal amount of debt owing by the Company as at a particular
date.
Forward-Looking Information
Certain information in
this press release, including the Company's expectation to
strengthen its brands, to achieve ongoing costs savings
initiatives, to identify and solicit strategic alternatives as part
of the strategic review process, relating to the realization of any
strategic transaction and the timing and terms thereof, and
challenging macroeconomic conditions generally constitutes
forward-looking information. In some cases, but not necessarily in
all cases, forward-looking information can be identified by the use
of forward-looking terminology such as "plans", "targets",
"expects" or "does not expect", "is expected", "an opportunity
exists", "is positioned", "estimates", "intends", "assumes",
"anticipates" or "does not anticipate" or "believes", or variations
of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", "will" or "will be
taken", "occur" or "be achieved". In addition, any statements that
refer to expectations, projections or other characterizations of
future events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts but instead represent management's expectations,
estimates and projections regarding future events.
The Board of Directors has previously announced that it
initiated a strategic review process to identify, review and
evaluate potential strategic alternatives that may be available to
the Company, including without limitation, the sale of all or
substantially all of the Company's securities and/or its assets, or
the raising of additional debt or equity capital. The Board has
engaged Piper Sandler & Co. as
its financial advisor to assist with identifying and soliciting
strategic alternatives. It is the Company's current intention not
to disclose developments with respect to the strategic review
process unless and until the Board has approved a specific
transaction or otherwise determines that disclosure is necessary or
appropriate. There can be no assurances or guarantees that the
strategic review process will result in a transaction or, if a
transaction is undertaken, the terms or timing of such a
transaction.
The terms of the credit facilities require the Company to
satisfy many affirmative and negative covenants and to meet certain
financial tests, including minimum Adjusted EBITDA and minimum
liquidity covenants, as more particularly described in the credit
facilities. In addition, the Company has agreed to launch the
aforementioned strategic review process by May 31, 2023, in accordance with a plan
(including key milestone dates) approved by the lenders. The
Company has required several amendments and extensions from its
lenders over the past eight months, and there is no assurance that
we will be able to meet the minimum Adjusted EBITDA and minimum
liquidity targets that we are required to achieve, and/or to
deliver or launch a strategic review plan that is satisfactory to
the lenders, in each case, to remain in compliance with the
foregoing covenants, among others. There can be no assurances or
guarantees that the approved strategic review plan will result in a
transaction or, if a transaction is undertaken, the terms or timing
of such a transaction. A failure by us to comply with the covenants
specified in the credit facilities could result in an event of
default, which would give the lenders the right to declare all
borrowings outstanding, together with accrued and unpaid interest
and fees, to be immediately due and payable. If the debt under the
credit facilities were to be accelerated, it is unlikely that the
Company would be able to repay (or refinance) the accelerated
indebtedness (including by way of selling sufficient assets) or
fulfill its obligations under certain contracts, and its future
financial condition, results of operations, prospects and/or
cashflows would be materially adversely affected. In such a
situation the Company would need to seek an additional amendment or
waiver of such covenants. The lenders under the credit facilities
may not consent to any amendment or waiver request that the Company
may make, and, if they do consent, they may only do so on terms
that are unfavorable or costly to the Company, and shareholders may
consequently lose some or all of their investment.
Forward-looking information is necessarily based on a number of
opinions, assumptions and estimates that, while considered
reasonable by MAV Beauty Brands as of the date of this press
release, are subject to known and unknown risks, uncertainties,
assumptions and other factors that may cause the actual results,
level of activity, performance or achievements to be materially
different from those expressed or implied by such forward-looking
information, including but not limited to the factors described in
greater detail in the "Risk Factors" section of the Company's most
recently filed Annual Information Form, the "Risk Factors" section
of the Company's most recently filed MD&A, and the Company's
other periodic filings made available at www.sedar.com. These
factors are not intended to represent a complete list of the
factors that could affect MAV Beauty Brands; however, these factors
should be considered carefully. There can be no assurance that such
estimates and assumptions will prove to be correct. The
forward-looking statements contained in this press release are made
as of the date of this press release, and MAV Beauty Brands
expressly disclaims any obligation to update or alter statements
containing any forward-looking information, or the factors or
assumptions underlying them, whether as a result of new
information, future events or otherwise, except as required by
law.
Q1 2023 Compared to Q1 2022
|
(in thousands of US
dollars) (unaudited)
|
|
Q1
2023
|
|
|
Q1
2022
|
|
|
$ Change
|
|
|
% Change
|
|
|
Consolidated
statements of operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
|
19,255
|
|
|
|
21,137
|
|
|
|
(1,882)
|
|
|
|
(8.9)
|
%
|
|
Cost of
sales
|
|
|
11,416
|
|
|
|
11,820
|
|
|
|
(404)
|
|
|
|
(3.4)
|
%
|
|
Gross profit
|
|
|
7,839
|
|
|
|
9,317
|
|
|
|
(1,478)
|
|
|
|
(15.9)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and
administrative
|
|
|
6,867
|
|
|
|
6,725
|
|
|
|
142
|
|
|
|
2.1
|
%
|
|
Loss on modification of
term loan
|
|
|
1,502
|
|
|
|
—
|
|
|
|
1,502
|
|
|
nmf
|
|
|
Amortization and
depreciation
|
|
|
776
|
|
|
|
1,100
|
|
|
|
(324)
|
|
|
|
(29.5)
|
%
|
|
Interest and
accretion
|
|
|
2,385
|
|
|
|
1,691
|
|
|
|
694
|
|
|
|
41.0
|
%
|
|
Foreign exchange
gain
|
|
|
(36)
|
|
|
|
68
|
|
|
|
(104)
|
|
|
|
(152.9)
|
%
|
|
Integration,
restructuring, and other
|
|
|
214
|
|
|
|
615
|
|
|
|
(401)
|
|
|
|
(65.2)
|
%
|
|
|
|
|
11,708
|
|
|
|
10,199
|
|
|
|
1,509
|
|
|
nmf
|
|
|
Loss before income
taxes
|
|
|
(3,869)
|
|
|
|
(882)
|
|
|
|
(2,987)
|
|
|
nmf
|
|
|
Income tax expense
(recovery)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred
|
|
|
—
|
|
|
|
(250)
|
|
|
|
250
|
|
|
nmf
|
|
|
|
|
|
—
|
|
|
|
(250)
|
|
|
|
250
|
|
|
nmf
|
|
|
Net loss for the
period
|
|
|
(3,869)
|
|
|
|
(632)
|
|
|
|
(3,237)
|
|
|
nmf
|
|
|
EBITDA
(1)
|
|
|
(708)
|
|
|
|
1,909
|
|
|
|
(2,617)
|
|
|
nmf
|
|
|
Adjusted EBITDA
(1)
|
|
|
1,282
|
|
|
|
2,873
|
|
|
|
(1,591)
|
|
|
|
(55.4)
|
%
|
|
Adjusted Net Income
(Loss) (1)
|
|
|
(2,386)
|
|
|
|
86
|
|
|
|
(2,472)
|
|
|
nmf
|
|
|
|
(1)
|
EBITDA, Adjusted
EBITDA and Adjusted Net Income (Loss) are each non-IFRS measures
and are not earning measures recognized by IFRS. Definitions and
reconciliations of non-IFRS measures to the relevant reported
measures can be found under the headings "Non-IFRS Measures" and
"Q1 2023 Compared to Q1 2022" in this press release. See also our
Management's Discussion and Analysis under the headings "How We
Assess the Performance of Our Business" on page 7, and "Non-IFRS
Measures" on page 9.
|
(in thousands of US
dollars) (unaudited)
|
|
Q1
2023
|
|
Q1
2022
|
|
Consolidated net
income (loss):
|
|
(2,367)
|
|
(632)
|
|
Income tax expense
(recovery)
|
|
—
|
|
(250)
|
|
Interest and
accretion
|
|
2,385
|
|
1,691
|
|
Amortization and
depreciation
|
|
776
|
|
1,100
|
|
EBITDA
|
|
794
|
|
1,909
|
|
Integration,
restructuring, and other
|
(1)
|
214
|
|
615
|
|
Share-based
compensation
|
(2)
|
265
|
|
263
|
|
Unrealized foreign
exchange loss
|
|
9
|
|
86
|
|
Adjusted
EBITDA
|
|
1,282
|
|
2,873
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands of US
dollars) (unaudited)
|
|
Q1
2023
|
|
Q1
2022
|
Consolidated net
income (loss):
|
|
(2,367)
|
|
(632)
|
Integration,
restructuring, and other
|
(1)
|
214
|
|
615
|
Share-based
compensation
|
(2)
|
265
|
|
263
|
Unrealized foreign
exchange loss
|
|
9
|
|
86
|
Tax impact of the
above adjustments
|
|
(124)
|
|
(246)
|
Adjusted Net Income
(Loss)
|
|
(2,003)
|
|
86
|
|
|
|
|
|
|
|
|
|
(1)
|
Refer to Note 10 to
the unaudited condensed consolidated interim financial
statements for further details.
|
(2)
|
Represents
recognition of share-based compensation, which have been accounted
for as selling and administrative expenses.
|
(in thousands of US
dollars) (unaudited)
|
|
Q1
2023
|
|
Q1
2022
|
|
YTD Q1
2023
|
|
YTD Q1
2022
|
Cash provided by
operating activities
|
|
(66)
|
|
3,728
|
|
(66)
|
|
3,728
|
Less: purchase of
property and equipment
|
|
(42)
|
|
(47)
|
|
(42)
|
|
(47)
|
Free Cash Flow and
Adjusted Free Cash Flow
|
|
(108)
|
|
3,681
|
|
(108)
|
|
3,681
|
SOURCE MAV Beauty Brands